March 15th, 2013
FDA Studying Whether Certain Diabetes Drugs Pose Pre-Cancer Risk
The FDA is investigating whether diabetes drugs in the class known as incretin mimetics pose an increased risk for pancreatic duct metaplasia.
The agency is looking at unpublished data on pancreatic toxicity in a small number of tissue samples taken from patients with diabetes who died. It will examine the researchers’ methodology and the samples firsthand before concluding whether there is a risk to patients.
Incretin mimetics include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). The drugs’ labels already carry warnings about the risk for pancreatitis.
Healthcare providers may continue prescribing the drugs according to the labels and should report adverse events to the FDA.
2 Responses to “FDA Studying Whether Certain Diabetes Drugs Pose Pre-Cancer Risk”
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?
Whether incretins as a class are responsible for pancreatic duct metaplasia, or uncontrolled diabetes per se , is a very controversial point. It takes years for mutations & cancer to occur, and incretins have been around for a few years only.
I think we should stick to conventional drugs viz.
Oral antidiabetics:-Insulin sensitisers-specifically metformin
and Secretagogues like glimeperide and human insulins (after
advising proper diet and exercise).Any patient who follows but fails to respond (which is rare) should be referred to a specialised clinic.
Reply
March 17,2013